VRTX
Vertex Pharmaceuticals Inc
NASDAQ: VRTX · HEALTHCARE · BIOTECHNOLOGY
$508.34
-1.55% today
Updated 2026-09-18
Market cap
$130.56B
P/E ratio
29.98
P/S ratio
10.38x
EPS (TTM)
$17.19
Dividend yield
—
52W range
$374 – $560
Volume
1.2M
WallStSmart proprietary scores
64
out of 100
Grade: C+
Hold
Investment rating
6.7
Growth
B8.5
Quality
A9.0
Profitability
A+6.7
Valuation
B3/9
Piotroski F-Score
Weak
3.6
Altman Z-Score
Safe zone
—
Industry rank
—
View all highly rated stocks (75+) →253 stocks currently score above 75
Price targets
Analyst target
$539.08
+6.05%
12-Month target
$450.07
-11.46%
Intrinsic (DCF)
$960.82
Margin of safety
+46.26%
4 Strong Buy19 Buy4 Hold1 Sell1 Strong Sell
Price chart
Stock snapshot
Strengths
+ Altman Z 3.61 — safe zone
+ Profit margin 35.00% — above average
+ ROE 21.76% — strong efficiency
+ Free cash flow $1.01B — positive
+ Revenue growth 12.50% QoQ
Risks
- Piotroski 3/9 — weak financial health
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM | 2026 (E) |
|---|---|---|---|---|---|---|
| Revenue | $8.93B | $9.87B | $11.02B | $12.07B | $12.59B | $13.3B |
| Net income | $3.32B | $3.62B | $-535.60M | $3.95B | $1.10B | — |
| EPS | — | — | — | — | $17.19 | $19.39 |
| Free cash flow | $3.93B | $3.28B | $-790.30M | $3.19B | $1.01B | — |
| Profit margin | 37.20% | 36.68% | -4.86% | 32.74% | 35.00% | — |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-09-08 | VAN, GRUNSVEN JASPER | Buy | 8,682 | — |
| 2026-08-28 | AMBROSE, KRISTEN | Buy | 5,000 | — |
| 2026-08-27 | SACHS, BRUCE I | Sale | 6,000 | — |
Peer comparison
Smart narrative
Vertex Pharmaceuticals Inc trades at $508.34. representing a P/E of 29.98x trailing earnings. Our Smart Value Score of 64/100 indicates the stock is good. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of 3.61, it sits in the safe zone. TTM revenue stands at $12.59B. with profit margins at 35.00%. Our DCF model estimates intrinsic value at $960.82.
Frequently asked questions
What is Vertex Pharmaceuticals Inc's stock price?
Vertex Pharmaceuticals Inc (VRTX) trades at $508.34, on a P/E of 30.0x and a P/S of 10.4x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Vertex Pharmaceuticals Inc overvalued?
Vertex Pharmaceuticals Inc carries a Smart Value Score of 64/100 (Grade C+), which we rate Hold. That score blends growth, quality, and valuation into one read. Our DCF puts intrinsic value at $960.82 versus the $508.34 price, a 46.3% margin of safety on a cash flow basis.
What is the price target of Vertex Pharmaceuticals Inc (VRTX)?
The 12-month analyst consensus target is $539.08, about 6.0% above the current $508.34. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is the intrinsic value of Vertex Pharmaceuticals Inc (VRTX)?
Our DCF model estimates intrinsic value at $960.82, a +46.3% margin of safety versus today's $508.34. Intrinsic value is what the projected cash flows are worth today. A positive reading means the price sits below that estimate, leaving a cushion if growth holds.
What is Vertex Pharmaceuticals Inc's revenue?
Vertex Pharmaceuticals Inc's trailing twelve-month revenue is $12.59B. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
Vertex Pharmaceuticals Inc's Altman Z-Score is 3.61, which places it in the safe zone. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio10.38x
ROE21.76%
Beta0.32
50D MA$510.30
200D MA$467.58
Shares out0.25B
Float0.25B
Short ratio—
Avg volume1.2M
Performance
1 week-1.38%
1 month-5.91%
3 months+12.56%
YTD+12.13%
1 year+32.68%
3 years—
5 years—